NEW YORK (GenomeWeb news) – Luminex reported after the close of the market on Wednesday that its third-quarter 2009 revenues rose nearly one percent, and it swung to a loss compared to a profit for the year-ago period.

The Austin, Texas-based molecular diagnostics instrumentation and assay maker had revenues of $29.1million for the three-month period ended Sept.30, compared to revenues of $28.9 million for the third quarter last year. Sales for its technology group fell to $22 million from $22.6 million, while sales for its assay group rose to $7.1 million from $6.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.